Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg (NCT00529451), a randomized phase 3 study. The primary outcome is Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP).

2. Clinical Question

3. Trial Design

This was a Phase 3 randomized, double-blind, multicenter, parallel-group, active-controlled study. It compared once-daily aliskiren at 300 mg, 150 mg, and 75 mg with once-daily ramipril 5 mg in patients with essential hypertension. The official title describes an eight-week study, and the primary endpoint timeframe is baseline to Week 8. The registry lists the study as completed, with enrollment of 1613.

The primary outcome was analyzed in an intent-to-treat population defined in the registry as patients who received at least one dose of study drug and had a post-baseline measurement. This definition identifies the conditions for inclusion in the posted primary analysis; details about handling missing endpoint measurements, withdrawals, protocol deviations, or analysis populations beyond that definition are not reported in the registry record. The primary endpoint analysis includes 327 patients assigned to aliskiren 300 mg and 323 assigned to ramipril 5 mg.

The study also included aliskiren 150 mg and 75 mg groups. Posted secondary results cover blood-pressure control at Week 8 and a responder definition based on msDBP at Week 8. The registry also lists changes in mean sitting systolic and diastolic blood pressure as secondary outcomes, but numerical results for those changes are not reported in the registry record. The enrollment total and outcome-specific analysis counts are different kinds of quantities and should not be treated as interchangeable.

The sponsor was Novartis. The registry lists the study start as 2007-09 and primary completion as 2008-07. Information about the randomization sequence, allocation concealment, specific blinding procedures, treatment adherence, and the trial’s original sample-size justification is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP), measured over Baseline and Week 8.

The primary endpoint is change from baseline to the Week 8 endpoint in mean sitting diastolic blood pressure (msDBP), expressed in mm Hg. It summarizes the average change in a continuous measurement across the analyzed participants in each group. Negative changes indicate that the follow-up group mean was lower than its baseline mean; the endpoint is a group-level summary, not a description of each participant’s individual response.

Comparing changes between randomized groups helps address whether the observed average change differs between the assigned treatments over the study period. The registry states that the primary objective was to evaluate whether aliskiren 300 mg was non-inferior to ramipril 5 mg. In general, a non-inferiority study asks whether the treatment difference is not worse than a prespecified margin. That margin and the associated decision rule are not reported in the registry record. Without them, a reader cannot determine from the numerical estimate and confidence interval alone whether the stated non-inferiority criterion was satisfied.

Blood pressure is also represented in the posted secondary outcomes as control to a target and as a responder classification. Those binary outcomes answer different questions from the continuous primary endpoint: they count participants meeting a specified category rather than describing the average change in a continuous measurement. The endpoint definition and timeframe therefore matter when interpreting whether two reported outcomes are consistent or distinct.

7. Results Posted in the Registry

• Ramipril 5 mg: mean -9.19 versus -11.63 on control; difference 2.44 (95% CI 1.22 to 3.66), standardized effect d = 0.31; z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of < 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Aliskiren 150 mg: 48.1% (153/318) versus 52.3% (171/327) on control; risk difference -4.2 percentage points (95% CI -11.9 to 3.5), risk ratio 0.92 (0.79–1.07); unadjusted two-proportion z-test p = 0.288.
  • Aliskiren 75 mg: 45.7% (148/324) versus 52.3% (171/327) on control; risk difference -6.6 percentage points (95% CI -14.3 to 1.0), risk ratio 0.87 (0.75–1.02); unadjusted two-proportion z-test p = 0.091.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Aliskiren 150 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Aliskiren 75 mg and the control. The interval gives the range of effects that remain compatible with the data.

Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP < 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Aliskiren 150 mg: 59.7% (190/318) versus 67.9% (222/327) on control; risk difference -8.1 percentage points (95% CI -15.5 to -0.7), risk ratio 0.88 (0.78–0.99); unadjusted two-proportion z-test p = 0.031.
  • Aliskiren 75 mg: 59.6% (193/324) versus 67.9% (222/327) on control; risk difference -8.3 percentage points (95% CI -15.7 to -1.0), risk ratio 0.88 (0.78–0.99); unadjusted two-proportion z-test p = 0.027.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Aliskiren 150 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Aliskiren 75 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes add two categorical views of blood-pressure status at Week 8: whether participants were controlled to the target threshold and whether they met the responder definition. Across these outcomes, the posted proportions are generally higher for aliskiren 300 mg than for the other treatment groups. The comparisons of the lower aliskiren doses with aliskiren 300 mg tend to point in the same direction across the two definitions. These patterns provide context alongside the primary continuous outcome, but they are not measurements of the same estimand.

The control outcome classifies participants using a target blood pressure of < 140/90 mmHg. The responder outcome is defined by msDBP below 90 mmHg or a decrease of at least 10 mmHg from baseline in msDBP. A participant can meet a categorical definition in ways that are not captured by a group mean alone, while a mean change can reflect the whole distribution rather than just the number crossing a threshold. The registry also lists secondary changes in mean sitting systolic and diastolic blood pressure, but numerical results for those outcomes are not reported in the registry record.

The primary comparison concerns aliskiren 300 mg versus ramipril 5 mg on continuous msDBP change and has a stated non-inferiority objective. The posted secondary comparisons instead contrast the lower aliskiren doses with aliskiren 300 mg for the binary endpoints. They therefore do not directly replicate the primary comparison or establish its non-inferiority criterion.

In general, secondary findings carry less confirmatory weight when many outcomes or comparisons are examined without a reported multiplicity plan. The secondary p-values are unadjusted, and the registry does not report a multiplicity procedure or a hierarchy among secondary outcomes. Their results are useful for describing patterns and generating questions, but should not be treated as independent confirmation of a prespecified primary conclusion.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint
• Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of < 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg
• Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP < 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP

9. Statistical Interpretation

10. Statistical Methods Explained

What does the continuous outcome summarize?

Mean sitting diastolic blood pressure is a continuous measurement, so the primary outcome is summarized as a mean change for each treatment group. The posted values are least-squares means, a statistical form of group mean that can be adjusted for terms in a model. The registry does not report the method or model details for the sponsor’s primary analysis, so the role of any adjustment in those reported values is not described. The group values are -11.63 mm Hg for aliskiren 300 mg and -9.19 mm Hg for ramipril 5 mg.

In general, a mean is useful for describing the center of a continuous distribution, but it does not show how widely individual measurements vary. The standard errors posted for these group estimates are 0.44 in each arm. A standard error describes the estimated sampling uncertainty of a statistic, such as a mean; it is not the standard deviation of individual participant measurements.

How should the recalculated contrast be read?

The unadjusted recalculation compares the group means using the contrast ramipril minus aliskiren. Its estimate is 2.44 mm Hg, with a 95% confidence interval from 1.22 to 3.66 and an unadjusted p-value of <0.001. This calculation uses the posted summary statistics rather than the sponsor’s reported model. The approximate pooled standard deviation used for the standardized effect calculation is 7.932, and the standardized effect estimate is 0.308. The pooled standard deviation is approximate because it was derived from the posted standard errors and analysis counts, rather than taken from a reported standard deviation.

In general, a difference estimate depends on which group is subtracted from which. Reversing the contrast changes the sign of the estimate and reverses the interval endpoints, without changing the underlying comparison. That is relevant when reading the recalculation alongside the sponsor’s estimate, which uses the opposite sign direction. The two estimates should not be treated as if their signs used the same reference order.

What does a confidence interval contribute?

In general, a confidence interval gives a range of values compatible with the estimate under the statistical method used. Its width conveys precision: narrower intervals indicate less sampling uncertainty than wider intervals, all else being equal. A confidence interval is not a range containing a stated proportion of individual participants’ outcomes, and it does not account for every possible source of bias or uncertainty. The recalculated interval is based on an unadjusted summary-statistic comparison; the sponsor’s interval comes from the registry’s own analysis, whose method is not reported.

Why distinguish difference testing from non-inferiority?

In general, a conventional test of a difference evaluates compatibility with a zero contrast. A non-inferiority analysis instead evaluates whether the result rules out an unacceptable disadvantage defined by a margin. That margin must be specified to interpret the decision. The registry identifies the primary question as non-inferiority but does not report the margin or decision rule. The recalculated p-value is an unadjusted comparison, not a substitute for the sponsor’s margin-based assessment.

How are the secondary binary outcomes analyzed?

The posted secondary measures report the percentage of participants meeting a definition at Week 8. In general, a risk difference compares the proportions in two groups by subtracting one proportion from the other. Its sign depends on the subtraction order. The recalculated estimates use aliskiren 300 mg as the reference group and compare the other aliskiren doses with it. For binary outcomes, confidence intervals describe uncertainty in the difference between proportions; they do not describe uncertainty about the definition itself.

The reported unadjusted p-values for secondary comparisons are tests of the recalculated risk differences. They are not adjusted for the presence of other outcomes or comparisons in the information available in the registry record. In general, when multiple comparisons are examined, the chance of at least one apparently unusual result can increase unless the analysis plan addresses multiplicity. The registry record does not report a multiplicity procedure.

What should the analysis counts and missing information signal?

The primary analysis counts are 327 and 323, while the secondary binary analyses have outcome-specific counts. Different counts can arise because endpoints can have different available data or analysis definitions, but the reason for these counts is not reported in the registry record. The primary analysis population is described as intent-to-treat with at least one dose and a post-baseline measurement; further missing-data methods, sensitivity analyses, and protocol-defined analysis populations are not reported.

In general, missing-data assumptions can affect estimates if the availability of measurements is related to outcome or treatment. An analysis limited to participants with post-baseline measurements should therefore be understood in light of the stated population and the absence of more detailed missing-data information. The registry record does not support assumptions about imputation, interim analyses, covariate adjustment, or the original statistical analysis plan.

11. Confidence Intervals and Precision

The recalculated primary contrast is 2.44 mm Hg, with a 95% confidence interval from 1.22 to 3.66. The interval lies on the positive side of zero under the stated ramipril-minus-aliskiren orientation. This indicates that, under the unadjusted method, the estimated group difference is not especially close to zero relative to the interval’s uncertainty. The interval does not, however, answer the margin-based non-inferiority question by itself.

The sponsor’s reported estimate is -2.44, with a 95% confidence interval from -3.63 to -1.25. It uses the opposite sign direction from the recalculation. Its interval also lies on one side of zero, but the registry record does not describe the sponsor’s analysis method or the non-inferiority margin. The interval therefore cannot be used to infer the sponsor’s criterion without those details. The registry identifies the analysis as non-inferiority or equivalence, but does not report a p-value for it.

In general, a confidence interval conveys the precision of an estimate under the analysis assumptions. It does not capture uncertainty due to possible bias, endpoint measurement issues, missing data, or choices not described in the registry. The recalculation is based on posted group summary statistics, and its pooled standard deviation is approximate. The sponsor estimate is the registry’s own reported analysis, but its analytic details are incomplete. These are distinct sources of information and should not be mistaken for a single interval.

The binary secondary comparisons also have confidence intervals. Their interpretation concerns risk differences for the specific Week 8 classifications, not the continuous blood-pressure change. Because multiple secondary comparisons are posted and a multiplicity adjustment is not reported, individual intervals and unadjusted p-values should be treated as exploratory or descriptive evidence rather than as a complete family-wise assessment.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning estimates are participants per arm for the continuous and binary outcomes in this study. They are not total event counts: the registry’s planning note distinguishes these participant-based outcomes from time-to-event outcomes, for which a total number of events would be used. The estimates are illustrations based on observed effects, not the study’s original enrollment target or a reconstruction of its original design.

The listed planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each planning scenario uses the stated fraction of the observed effect as the effect to detect. The 80% power column describes the number of participants per arm estimated to give an 80% chance of detecting that assumed effect under those planning assumptions, if the effect and model assumptions hold. The 90% power column gives the corresponding per-arm estimate for a higher chance of detecting the same assumed effect.

Rows that plan for 100% of the observed effect use the full observed contrast as the planning target; rows for 75% or 50% of the observed effect target smaller contrasts. Smaller effects are harder to distinguish from random variation, so they require more participants under the same assumptions. The values are planning illustrations, not a guarantee that a future study would achieve the stated power. This is not observed power.

The registry record does not report the trial’s own original sample-size assumptions or justification. Accordingly, these illustrations should not be read as evidence about whether the completed study was designed around a particular effect size, power target, or allocation rationale. They address hypothetical planning under the listed assumptions only.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 2.440; pooled standard deviation σ = 7.932.
2. n = 2 × (1.96 + 0.842)² × 7.932² / 2.440² = 165.9, rounded up to 166 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 2.44                      # observed difference in means
sigma <- 7.9323634639026                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(529451)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 166 (80% power), 223 (90% power)
 75% of observed effect: n per arm = 295 (80% power), 395 (90% power)
 50% of observed effect: n per arm = 664 (80% power), 889 (90% power)
power.t.test: 166.9 
Simulated power at n = 166 per arm: 0.796 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports the sponsor’s primary comparison as a mean difference in final values of -2.44, with a 95% confidence interval from -3.63 to -1.25. It labels this a non-inferiority or equivalence analysis. The analysis method and p-value are not reported in the registry record. The primary endpoint description, by contrast, identifies change from baseline to the Week 8 endpoint. Because the sponsor’s reported analysis is described as using final values, the registry does not give enough detail to establish exactly how that analysis relates to the stated change endpoint.

The recalculated contrast is a simple unadjusted comparison from the posted group summaries and is expressed as ramipril minus aliskiren. Its estimate is 2.44, with a 95% confidence interval from 1.22 to 3.66. The sponsor estimate has the opposite sign direction, so the signs should not be compared as if the contrasts were ordered identically. The recalculation is not a replacement for the sponsor’s analysis and does not supply its missing model details or non-inferiority margin.

The registry record does not flag a discrepancy between the posted sponsor analysis and the recalculation. Even so, they are not identical statistical procedures: one is the registry’s sponsor-reported analysis and the other is an unadjusted recalculation from summary statistics. The sponsor’s own analysis is the relevant source for the trial’s stated non-inferiority assessment, but the missing margin and decision rule prevent an independent evaluation of that conclusion from the registry record alone.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists several outcomes: the primary change in msDBP and secondary measures that include changes in sitting systolic and diastolic pressure, target control, and responder status. It also reports multiple treatment groups and more than one secondary comparison. When multiple statistical questions are examined, multiplicity becomes relevant because a collection of unadjusted tests can produce apparently notable findings by chance even if no individual treatment effect is present.

The secondary comparisons are accompanied by unadjusted p-values. A multiplicity adjustment, testing hierarchy, or other procedure for controlling the interpretation of multiple comparisons is not reported in the registry record. It is therefore not possible to determine whether the secondary tests were intended to be confirmatory, how their order was set, or whether the reported p-values were adjusted elsewhere. The statistical analysis plan is not reported in the registry record.

The primary question is labelled non-inferiority, but the margin and decision rule are not reported. The analysis method for the sponsor’s primary result is also not reported. Those omissions matter because non-inferiority interpretation depends on a prespecified boundary and an analysis appropriate to the question. A conventional difference test or an unadjusted recalculation cannot fill in those missing design details.

The primary population is described as intent-to-treat patients who received at least one dose and had a post-baseline measurement. This definition indicates that the primary analysis did not include everyone enrolled automatically; eligibility depended on treatment exposure and a post-baseline measurement. The registry does not report how missing observations were handled, whether any imputation was used, or whether sensitivity analyses assessed alternative assumptions. It also does not report results for other analysis populations or explain the differing outcome-specific counts.

Details about interim analyses, covariate selection, randomization procedures, and the original statistical analysis plan are not reported in the registry record. Their absence should be treated as uncertainty about what can be verified from the record, not as evidence that a particular method was or was not used.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: head injury (0.3%), drug eruption (0.3%), hypertension (0.3%), varicose vein (0.3%), chest pain (0.3%).

The registry lists serious adverse events among 331 participants at risk in the aliskiren 300 mg group, 323 in the aliskiren 150 mg group, 332 in the aliskiren 75 mg group, and 329 in the ramipril 5 mg group. The numbers of participants recorded as affected by serious adverse events are 1, 2, 3, and 1, respectively. These are registry counts, not comparative estimates adjusted for exposure time or other factors. The record does not provide deaths data; death counts are not reported in the registry record.

The registry also lists the most frequent serious adverse-event terms as Head injury, Drug eruption, Hypertension, Varicose vein, Chest pain, and Medical device complication, each with a reported frequency of 0.3%. The record gives no further detail about event timing, severity grading, relatedness assessment, or event-specific group allocation in this listing. Those details are not reported in the registry record.

Serious adverse-event counts and non-serious adverse-event counts are distinct. The registry lists other adverse events separately, but those figures should not be conflated with serious events. In general, small counts provide limited information about comparative safety, and differences in observed counts alone do not establish causality or a stable difference between treatments.

17. What the Result Does, and Does Not, Mean

The posted results describe average blood-pressure changes and Week 8 categorical outcomes in a randomized, double-blind comparison of aliskiren doses with ramipril in patients with essential hypertension. For the primary comparison, the group mean change was more negative for aliskiren 300 mg than for ramipril 5 mg, and the unadjusted recalculation estimates a difference with a confidence interval that does not include zero. The sponsor’s reported result uses the opposite sign direction. These estimates describe group-level measurements over the study timeframe.

The registry identifies the primary objective as non-inferiority, but does not report the non-inferiority margin or the decision rule. Consequently, the posted numerical comparison alone cannot establish whether the prespecified non-inferiority requirement was satisfied. The sponsor’s own analysis is labelled non-inferiority or equivalence, but its method is not reported. A statistically detectable difference and a non-inferiority conclusion are different questions.

The results do not establish what happens beyond the Week 8 endpoint, because longer-term results are not reported in the registry record. They also do not describe outcomes that were not listed, and they cannot show how each individual participant’s measurement changed from a group average. The secondary binary outcomes summarize target attainment and responder status, which are related to, but not interchangeable with, the primary continuous measure.

The safety counts are descriptive registry figures. They do not by themselves establish that an event was caused by a treatment, nor do the counts provide a complete picture of all possible risks. The registry record does not report deaths data or several event details needed for a deeper comparison. Interpretation should remain limited to the posted outcome definitions, analysis populations, and timeframes.

Overall, the record supports a statistical description of the reported trial outcomes, not an individual treatment recommendation. The incomplete reporting of the sponsor’s non-inferiority framework, missing-data methods, and multiplicity procedures limits the strength of conclusions that can be drawn from the registry record alone.

18. Why This Trial Matters Statistically

This trial illustrates why the estimand and the contrast direction matter. The primary endpoint is change in a continuous measurement, and the recalculation expresses the treatment contrast as ramipril minus aliskiren. The sponsor’s reported estimate uses the reverse sign direction. Without making that ordering explicit, readers could mistake opposite signs for contradictory findings. The same principle applies to binary risk differences, whose signs depend on the order of subtraction.

The record also distinguishes a conventional difference comparison from a non-inferiority question. A result can be estimated precisely enough to suggest a difference from zero while still requiring a prespecified margin to address non-inferiority. Here, the registry states the non-inferiority objective but does not report the margin or decision rule. This makes the difference between an available numerical estimate and a verifiable trial conclusion especially important.

The posted secondary outcomes show why multiple endpoints need a clear interpretation plan. Continuous changes, target-control percentages, and responder classifications represent different summaries of outcomes. Their apparent consistency can add context, but unadjusted tests across multiple outcomes do not have the same role as a prespecified primary analysis. Missing information about multiplicity makes it difficult to know how strongly to weigh individual secondary findings.

Finally, the analysis population and outcome-specific counts are central to understanding the evidence. The primary analysis is defined by treatment exposure and a post-baseline measurement, while the total enrollment is a separate figure. The registry record does not explain all count differences or describe missing-data sensitivity analyses. These reporting distinctions are not technical footnotes: they shape what the estimated effects can reasonably represent.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record leaves important details of the primary non-inferiority analysis unspecified. It does not report the non-inferiority margin, decision rule, sponsor analysis method, or p-value. The sponsor result is described as a mean difference in final values, whereas the primary endpoint description refers to change from baseline to Week 8. The available record does not explain that distinction or give enough analysis detail to reconcile the two descriptions fully.

The recalculated primary contrast is unadjusted and based on posted summary statistics. Its pooled standard deviation is approximate. It should not be interpreted as a reproduction of a model-based sponsor analysis. The reported p-value for the recalculation is unadjusted, and the record does not establish whether any model covariates or other adjustments were included in the sponsor’s analysis.

The registry lists multiple secondary endpoints and comparisons, but does not report multiplicity control or a testing hierarchy. The secondary p-values therefore should not be read as if they came from a single prespecified confirmatory test. Numerical results for the listed secondary changes in mean sitting systolic and diastolic blood pressure are not reported in the registry record.

The primary population requires at least one dose and a post-baseline measurement. Missing-data handling, sensitivity analyses, and results for other analysis populations are not reported. The reasons for outcome-specific analysis counts are also not reported. These gaps limit assessment of how missing measurements or exclusions may have affected the estimates.

The safety record provides affected-participant counts and selected serious-event terms, but does not report death counts or detailed information about timing, duration, relatedness, or event severity. The study timeframe is eight weeks, so the posted results do not provide evidence about longer-term outcomes. The registry also does not report the original sample-size justification or detailed randomization and blinding procedures.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg — NCT00529451.
• Registry record last updated 2011-03-25; status last verified 2011-02.
• Results first posted 2011-03-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

This completed Phase 3 study randomized patients with essential hypertension in a double-blind, multicenter, parallel-group comparison of once-daily aliskiren 300 mg, 150 mg, or 75 mg with ramipril 5 mg. Enrollment was 1613, and the study was described as eight weeks long. The primary outcome was change from baseline to Week 8 in mean sitting diastolic blood pressure, with a stated non-inferiority objective for aliskiren 300 mg versus ramipril 5 mg.

The unadjusted recalculation of the primary comparison reports a mean difference of 2.44 mm Hg in the ramipril-minus-aliskiren direction, with a 95% confidence interval from 1.22 to 3.66 and p < 0.001. The sponsor’s reported estimate is -2.44, with a 95% confidence interval from -3.63 to -1.25, in the opposite direction. The registry does not report the non-inferiority margin, decision rule, or sponsor analysis method.

Secondary Week 8 outcomes cover target control and responder status. The registry record does not report multiplicity procedures, detailed missing-data methods, or numerical results for all listed secondary outcomes. Safety figures include serious adverse-event counts by group, while deaths data are not reported in the registry record.